Gene Amplification Market Projected to Reach $28.0 Billion by 2035
Gene amplification market was valued at $17.6 billion in 2025 and is projected to reach $28.0 billion by 2035, growing at a CAGR of 4.8% during the forecast period (2026-2035). Multiplex PCR is emerging as a key advancement within the global gene amplification market, offering high-throughput capabilities through the simultaneous amplification of multiple gene targets in a single reaction. This technology significantly enhances operational efficiency by reducing turnaround time from days to hours, while also minimizing reagent consumption and overall testing costs. As a result, multiplex PCR is increasingly being adopted across critical applications such as infectious disease diagnostics and oncology mutation profiling, where rapid and accurate multi-target detection is essential. The ability to detect multiple pathogens or genetic variations in a single run not only improves diagnostic accuracy but also streamlines laboratory workflows and supports faster clinical decision-making. From a market perspective, this efficiency is translating into higher demand for multiplex PCR kits and integrated platforms, particularly in high-volume testing environments.
Browse the full report description of “Gene Amplification Market Size, Share & Trends Analysis Report by Product Type (Instruments, Reagents & Consumables, Software & Services), by Technology Type (Conventional PCR, Real-Time PCR, Digital PCR, and Isothermal Amplification), and by Application (Clinical Diagnostics, Research Applications, Forensic Science, Agriculture & Food Testing, and Environmental Testing), Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/gene-amplification-market
The increasing commercialization of multiplex PCR technologies in emerging economies, where expanding healthcare infrastructure and rising investments in molecular diagnostics are driving uptake. Countries across Asia-Pacific and Latin America are witnessing strong demand due to cost-effective testing needs and large patient populations. For instance, in December 2024, Indian Council of Medical Research signed a technology transfer agreement with Molbio Diagnostics Pvt. Ltd. to commercialize EnViro-Q, India’s first multiplex real-time RT-PCR assay for detecting enteric viruses. Developed by ICMR-National Institute for Research in Bacterial Infections, the diagnostic tool enables rapid and accurate detection of viral gastroenteritis, helping reduce misdiagnosis and unnecessary antibiotic use. The collaboration aims to expand global access to this cost-effective test, particularly in public health systems, to improve timely diagnosis and outcomes in pediatric care. Overall, multiplex PCR is transitioning into a scalable and commercially viable solution, reinforcing its role as a significant growth driver in the global gene amplification market.
Key Players and Recent Innovations in the Global Gene Amplification Market
The global gene amplification market is led by major biotechnology and diagnostics companies focused on advancing molecular testing technologies for rapid, accurate, and high-throughput applications. Key players include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Bio-Rad Laboratories, Inc., and Agilent Technologies, Inc., among others. These companies are actively innovating to improve diagnostic efficiency, enhance multiplexing capabilities, and support rapid detection of infectious diseases and other genetic conditions.
- In September 2024, Roche launched the cobas Respiratory flex test, the first diagnostic assay to use its TAGS (Temperature-Activated Generation of Signal) technology for high-throughput detection of up to 12 respiratory viruses in a single patient sample. The test enables rapid, accurate, and flexible multiplex PCR testing on cobas 5800, 6800, and 8800 systems, supporting timely diagnosis and optimized antimicrobial use. TAGS technology also allows differentiation of up to 15 pathogens per test, with potential applications across multiple infectious diseases in central laboratory settings.
- In March 2024, Co-Diagnostics, Inc. announced that its joint venture, CoSara Diagnostics Pvt Ltd, received clearance from India’s Central Drugs Standard Control Organization (CDSCO) to market the SARAPLEX Influenza Multiplex PCR Test Kit. The test, built on Co-Diagnostics’ patented Co-Primers technology, enables simultaneous detection and differentiation of multiple Influenza A and B strains, improving accuracy in high-throughput clinical laboratories.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- Product Type
- Technology Type
- Application
- Competitive Landscape – Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Bio-Rad Laboratories, Inc. and Agilent Technologies, Inc., among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Gene Amplification Market Report Segment
By Product Type
- Instruments
- Reagents & Consumables
- Software & Services
By Technology Type
- Conventional PCR
- Real-Time PCR
- Digital PCR
- Isothermal Amplification
By Application
- Clinical Diagnostics
- Research Applications
- Forensic Science
- Agriculture & Food Testing
- Environmental Testing
Global Gene Amplification Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/gene-amplification-market